Neurocrine Biosciences Selected Ruder Finn for PR Duties
The pharmaceutical firm appointed the agency to manage its corporate and product communications strategy.
Updated on Sept. 29, 2026 in Advertising
Live Poll
Do you trust large corporations more when they handle their own communications in-house?
Neurocrine Biosciences named Ruder Finn as its U.S. agency of record following a competitive review. The partnership covers product and pipeline communications along with digital and creative strategy.
Why it matters
The appointment consolidates Neurocrine’s communications efforts across its neuropsychiatry and endocrinology business units. The company, which generated $2.86 billion in 2025 revenue, initiated this change to align its external messaging and corporate reputation.
Neurocrine Biosciences reported $2.86 billion in total revenue for 2025. The firm has now centralized its communications strategy under Ruder Finn after completing a competitive review.
The players
Neurocrine Biosciences
A San Diego-based pharmaceutical company focused on neuroscience-related health conditions.
Ruder Finn
A global communications agency that provides digital, creative, and reputation strategy services.
Kelley Yoder
The senior counsel at Ruder Finn serving as the primary relationship lead for the account.
Christie Anbar
An executive at Ruder Finn who co-leads the account and oversees product-specific strategy.
Kate Hardin
The lead for corporate communications at Neurocrine Biosciences.
The details
Ruder Finn is now responsible for the company’s product and pipeline communications, alongside broader corporate reputation management. The remit includes specialized digital and creative work for Neurocrine’s core business segments in neuropsychiatry and endocrinology. The engagement, led by Kelley Yoder and Christie Anbar, officially commenced in July 2026.
Timeline
2025: Neurocrine Biosciences generated $2.86 billion in revenue.
July 2026: Ruder Finn began the account engagement.
September 29, 2026: The agency of record status was publicly announced.
Market Landscape
This consolidation follows the standard industry pattern of using competitive agency reviews to align communications across distinct product pipelines. The shift marks a move toward a centralized creative and digital strategy for Neurocrine as it scales its endocrinology and neuropsychiatry portfolios.
Operators should observe how centralized agency mandates impact the speed and consistency of corporate messaging during product launches. Assess whether your current external communications partners can scale digital and creative services alongside your firm's revenue growth.
The takeaway
Centralizing communications under one agency of record allows for better integration between product strategy and corporate reputation. Operators should review their own agency contracts to ensure they include comprehensive digital and creative support as their portfolios evolve.
Further reading
For more on industry shifts, visit the Advertising section.
Source note: This article includes information reported by PRovoke Media.
Live Poll
Do you trust large corporations more when they handle their own communications in-house?
